Blog / Archives
Biotechnology Archives: Human Genome Sciences-Anthrax and Lupus
1999 Biotech Superstar Got Bailed Out By Anthrax antitoxin?! The famous Company that was going to revolutionize drug discovery was saved in 2003 by a government funded bioterror program for Anthrax...
Major Sell-Off in Biopharmaceutical Stocks: Caution and Raise Cash -Update 1
Damage held to the AM-IBB Holds at $180 Two Volatile Stocks Green stocks in our coverage universe: ACHN, BIIB, CBST. Volume on all biotech stocks was above average, so review technicals as this...
Emerging Biomarker Companies Redux: BGMD,RGDX,VRML Positioned for Growth
Biomarker Products for Cardiovascular Disease and Cancer This is the third article on Emerging Biomarker Companies. See 11/15/12 Update The synergies between diagnostics and drugs are growing as...
Bull Market Rolls On And Biotech Sector Hits New All Time Highs
BioBubble with No Trouble? Another green screen today with the usual suspects running in Rayno Biopharmaceuticals helped by the Bank of America Health Care Conference. Alexion (ALXN) up 2.86%,...
VRML Soars 40% On Equity Infusion: Biomarker Face-Off Redux with BGMD,RGDX
Vermillion Gets Equity Infusion from Oracle Partners, Others: VRML Soars 36% By popular demand and continuing interest in three emerging micro-cap stocks we are updating coverage. This is triggered...
Oncology Pipeline Analysis from Linda Pullan: ASCO Primer
ASCO Meeting Coming Up May 31 With the ASCO Meeting coming up at the end of the month, we are pleased to provide oncology pipeline data from Linda Pullan. There was a lot of interest on this WEB...
Rayno Life Science Diagnostics and Tools: Big Winners ABAX,ILMN,NEOG,QDEL,TMO
Rayno Diagnostics and Tools-Awaiting Q1 Results Many Rayno Diagnostics and Tools stocks have made new highs recently despite the sector being less frothy than biopharmaceuticals. These stocks are...
Rayno Life Science Update: A Little Profit Taking With Sector Up 30% YTD
Rayno Biopharma Portfolio We are still cautious on adding new biotech positions except stocks that were mentioned last month (see Alkermes ALKS, Array ARRY and Achillion ACHN). Many biotech MO...
Targeted Therapy and Diagnostic Biomarker Studies and Services 3/3/13 Update GHDX
Genomic Health Up 5% on Higher Q1 Revenues An article in the New York Times today (May 2) by Gina Kolata reviewed studies that affirmed the genetic basis of cancer. Genetic analysis of hundreds of...
Bit of a Blah Risk-Off Day- Except Regeneron (REGN) Up 14%
Regeneron (REGN) Up 30 Points On Allergan Delays For Vision Loss Drug As news came out from an Allergan (AGN $98.5) off 12%, conference call that their vision loss drug would be delayed, Regeneron...